etamicastat

structure in first source

Also Known As:

5-(2-aminoethyl)-1-(6,8-difluorochroman-3-yl)-1,3-dihydroimidazole-2-thione; 5-(2-aminoethyl)-1-(6,8-difluorochroman-3-yl)-1,3-dihydroimidazole-2-thione hydrochloride; BIA 5-453; BIA-5-453

Networked: 6 relevant articles (1 outcomes, 5 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Imidazoles: 150
      - etamicastat: 6
  - Pyrans: 130
    - Benzopyrans: 195
      - etamicastat: 6
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Benzopyrans: 195
      - etamicastat: 6

Experts

1.	Soares-da-Silva, Patricio: 3 articles (03/2016 - 06/2011)
2.	Soares-da-Silva, Patrício: 2 articles (05/2018 - 01/2015)
3.	Igreja, Bruno: 2 articles (03/2016 - 01/2015)
4.	Almeida, Luis: 2 articles (12/2013 - 06/2011)
5.	Nunes, Teresa: 2 articles (12/2013 - 06/2011)
6.	Vaz-da-Silva, Manuel: 2 articles (12/2013 - 06/2011)
7.	Dey, Sanjay Kumar: 1 article (09/2020)
8.	Kundu, Suman: 1 article (09/2020)
9.	Prabhakar, Pankaj: 1 article (09/2020)
10.	Saini, Manisha: 1 article (09/2020)

Related Diseases

1.	Hypertension (High Blood Pressure) 12/01/2013 - "This study assessed the tolerability, pharmacokinetics, and pharmacodynamics of etamicastat in patients with arterial hypertension. " 01/01/2015 - "In conclusion, inhibition of peripheral DβH with etamicastat, as a monotherapy or combination therapy, may constitute a valid alternative treatment for high blood pressure. " 09/01/2020 - "Inhibitors of DBH have been successful in combating hypertension, as evidenced by the outcome of clinical trials for etamicastat and zamicastat. " 03/01/2016 - "The aim of the present study was to evaluate the influence of chronic inhibition of dopamine ß-hydroxylase by etamicastat on the development of hypertension in the spontaneously hypertensive rat (SHR) and the sustainability of effects on the systolic and diastolic blood pressure in the SHR and the normotensive Wistar-Kyoto rat (WKY). " 03/01/2016 - "Chronic dopamine ß-hydroxylase inhibition with etamicastat effectively decreases BP, although does not prevent the development of hypertension in the SHR."
2.	Breast Neoplasms (Breast Cancer) 05/30/2018 - "Thus, the purpose of the study herein presented was to explore the interaction of P-glycoprotein (P-gp) and Breast Cancer Resistance Protein (BCRP), the two major efflux transporters of the BBB that hamper the entry of several drugs to the brain, with the DBH inhibitors, etamicastat, nepicastat and zamicastat. "
3.	Heart Failure 12/01/2013 - "Etamicastat is a dopamine β-hydroxylase (DβH) inhibitor currently in clinical development for the treatment of hypertension and heart failure. " 06/01/2011 - "Etamicastat is a new dopamine-β-hydroxylase (DβH) inhibitor currently in clinical development for the treatment of hypertension and heart failure. "
4.	Tachycardia (Tachyarrhythmias) 01/01/2015 - "Etamicastat monotherapy induced a dose-dependent reduction in blood pressure without reflex tachycardia. "

Related Drugs and Biologics

1.	Mixed Function Oxygenases (Monooxygenases)
2.	Dopamine (Intropin)
3.	Antihypertensive Agents (Antihypertensives)
4.	zamicastat
5.	Member 1 Subfamily B ATP Binding Cassette Transporter
6.	Proteins (Proteins, Gene)
7.	nepicastat

Related Therapies and Procedures

1.	Therapeutics